HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
B 220
structure given in first source
Also Known As:
2,3-dimethyl-6-(dimethylaminoethyl)-9-hydroxy-6H-indolo-(2,3-b)quinoxaline; 2,3-dimethyl-N,N-dimethylaminoethyl-5H-indolo(2,3-b)quinoxaline; 9-OH-B220; B-220
Networked:
2
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Quinoxalines: 324
B 220: 2
Indoles: 200
B 220: 2
Experts
1.
Boni, Luigi
: 1 article (10/2016)
2.
Cassinotti, Elisa
: 1 article (10/2016)
3.
Clerici, Federico
: 1 article (10/2016)
4.
Frattini, Paolo
: 1 article (10/2016)
5.
Roscio, Francesco
: 1 article (10/2016)
6.
Scandroglio, Ildo
: 1 article (10/2016)
Related Diseases
1.
Rectal Neoplasms (Rectal Cancer)
10/01/2016 - "
Group A included 96 and 33 patients, and Group B 220 and 82 for colon and rectal cancers, respectively.
"
2.
Papilloma (Papillomatosis)
09/30/1999 - "
Moreover, if B-220 treatment was terminated after 20 weeks and TPA treatment continued, papilloma development resumed indicating that initiated tumor cells were still present but were unable to grow with B-220 present.
"
09/30/1999 - "
Administration of B-220 1 h before TPA promotion resulted in a prolonged latency period of tumor appearance and a significantly reduced (up to 15% of positive controls) papilloma yield at 20 weeks.
"
09/30/1999 - "
B-220 administration before BPO promotion had no effect on the appearance of BPO induced papillomas or epidermal hyperplasia, suggesting that TPA and BPO promote tumor formation via at least partially different mechanisms.
"
3.
Neoplasms (Cancer)
09/30/1999 - "
In conclusion, we present evidence that B-220 is a potent inhibitor of mouse skin tumor promotion by TPA, but has little effect on the initiation step or the survival of initiated cells.
"
09/30/1999 - "
If B-220 pretreatment was not given during the first 10 weeks of TPA promotion, incidence at 20 weeks was not reduced but tumor multiplicity was still decreased.
"
09/30/1999 - "
Moreover, if B-220 treatment was terminated after 20 weeks and TPA treatment continued, papilloma development resumed indicating that initiated tumor cells were still present but were unable to grow with B-220 present.
"
09/30/1999 - "
Administration of B-220 1 h before TPA promotion resulted in a prolonged latency period of tumor appearance and a significantly reduced (up to 15% of positive controls) papilloma yield at 20 weeks.
"
09/30/1999 - "
B-220 administration before BPO promotion had no effect on the appearance of BPO induced papillomas or epidermal hyperplasia, suggesting that TPA and BPO promote tumor formation via at least partially different mechanisms.
"
4.
Hyperplasia
09/30/1999 - "
B-220 administration before BPO promotion had no effect on the appearance of BPO induced papillomas or epidermal hyperplasia, suggesting that TPA and BPO promote tumor formation via at least partially different mechanisms.
"